Toleranzia Overview
- Year Founded
-
2011
- Status
-
Private
- Employees
-
10
- Latest Deal Type
-
Buyout/LBO
- Financing Rounds
-
5
Toleranzia General Information
Description
Developer of biotechnology intended to treat autoimmune orphan diseases. The company's technology utilizes a proprietary platform to restore immunological tolerance and target underlying disease causes, providing pharmaceutical partners with drug candidates for neuromuscular and blood vessel conditions.
Contact Information
Website
www.toleranzia.seCorporate Office
- Arvid Wallgrens backe 20, 8 Trappor
- 413 46 Gothenburg
- Sweden
Corporate Office
- Arvid Wallgrens backe 20, 8 Trappor
- 413 46 Gothenburg
- Sweden
Toleranzia Timeline
Toleranzia Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Toleranzia Comparisons
Industry
Financing
Details
Toleranzia Competitors (46)
One of Toleranzia’s 46 competitors is Agomab Therapeutics, a Formerly VC-backed company based in Antwerp, Belgium.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Agomab Therapeutics | Formerly VC-backed | Antwerp, Belgium | ||||
| CSL Behring | Corporation | King Of Prussia, PA | ||||
| Baliopharm | Venture Capital-Backed | Basel, Switzerland | ||||
| Prothena | Corporation | Dublin, Ireland | ||||
| Prevail Therapeutics | Formerly VC-backed | New York, NY |
Toleranzia Patents
Toleranzia Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2024186255-A1 | Combination treatment of autoimmune disease, comprising acetylcholine receptor peptide | Inactive | 09-Mar-2023 | ||
| US-20240270816-A1 | Fusion protein for treating myasthenia gravis | Pending | 07-Jun-2021 | ||
| WO-2022260579-A3 | Fusion protein for treating myasthenia gravis | Inactive | 07-Jun-2021 | ||
| WO-2022260579-A2 | Fusion protein in myasthenia gravis | Inactive | 07-Jun-2021 | ||
| WO-2013160865-A1 | Immunotolerizing fusion proteins for treatment of multiple sclerosis | Inactive | 26-Apr-2012 | A61K39/0007 |
Toleranzia Signals
Toleranzia Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Toleranzia FAQs
-
When was Toleranzia founded?
Toleranzia was founded in 2011.
-
Where is Toleranzia headquartered?
Toleranzia is headquartered in Gothenburg, Sweden.
-
What is the size of Toleranzia?
Toleranzia has 10 total employees.
-
What industry is Toleranzia in?
Toleranzia’s primary industry is Drug Discovery.
-
Is Toleranzia a private or public company?
Toleranzia is a Private company.
-
What is Toleranzia’s current revenue?
The current revenue for Toleranzia is .
-
How much funding has Toleranzia raised over time?
Toleranzia has raised $2.52M.
-
Who are Toleranzia’s investors?
Flerie has invested in Toleranzia.
-
Who are Toleranzia’s competitors?
Agomab Therapeutics, CSL Behring, Baliopharm, Prothena, and Prevail Therapeutics are some of the 46 competitors of Toleranzia.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process